Covid‐19 and exacerbation of psoriasis

Özaras, Reşat; Berk, A. Tülin; Ucar, Dilek Hasman; Duman, Habibe; Kaya, Fatma Nur; Mutlu, Haşim

doi:10.1111/dth.13632

Cited by 63 publications

(65 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…So far (August 2020), two cases of plaque psoriasis and one case of guttate psoriasis have been reported secondary to COVID-19. [4][5][6] Ozaras et al, who reported one case of plaque psoriasis, found that after COVID-19 treatment, the patient's psoriatic lesions also regressed without any specific treatment 4 ; in other words, COVID-19 was responsible for these lesions. Here, we reported the first case of pustular psoriasis, exacerbated by COVID-19.…”

Section: Covid-19 and The Positive Results Of Polymerase Chain Reactimentioning

confidence: 99%

Pustular psoriasis exacerbated by COVID ‐19 in a patient with the history of psoriasis

Shakoei

Ghanadan

Hamzelou

2020

Dermatologic Therapy

View full text Add to dashboard Cite

The recent coronavirus disease (COVID-19), which was first reported in China, has spread around the world, causing major public health concerns. 1 Several treatments have been proposed for the treatment of COVID-19, including hydroxychloroquine, monoclonal antibodies, corticosteroids, favipiravir, lopinavir/ritonavir, anticoagulants, and azithromycin. 2 Here, we present a case of pustular psoriasis, exacerbated by COVID-19 in a patient with a history of hydroxychloroquine use. Patient consent for publication is achieved. The patient was a 47-year-old woman, presenting with pustular lesions over the past 3 weeks. The COVID-19 symptoms, including sore throat, myalgia, fever, and dry cough (for 8 days), had developed over the past 6 weeks. The chest computed tomography (CT) scan showed bilateral peripheral ground-glass opacities and infiltrations. Oxygen saturation was in the normal range. She was tested for

show abstract

Section: Covid-19 and The Positive Results Of Polymerase Chain Reactimentioning

confidence: 99%

Pustular psoriasis exacerbated by COVID ‐19 in a patient with the history of psoriasis

Shakoei

Ghanadan

Hamzelou

2020

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Flares of psoriasis or newly-developed psoriatic arthritis concurrent with or following COVID-19 infection had been reported. These conditions had resolved either spontaneously or after NSAID and topical corticosteroids treatment (139)(140)(141). In summary, cutaneous vasculitis were potentially associated with COVID-19 infection, mainly in the Western population.…”

Section: Skin Manifestationsmentioning

confidence: 96%

Autoimmune and Rheumatic Manifestations Associated With COVID-19 in Adults: An Updated Systematic Review

2021

View full text Add to dashboard Cite

Background: Numerous cases of the coronavirus disease 2019 (COVID-19) with autoimmune and rheumatic manifestations have been reported. Despite the available reviews that summarized its autoimmune/rheumatic manifestations, a systematic approach is still lacking. Therefore, we conducted a comprehensive systematic review in order to give an overview upon these rare but clinically significant manifestations.Methods: We performed a literature search of PubMed and EMBASE as of October 9, 2020. All articles relevant to either systemic or organ-specific autoimmune and rheumatic manifestations potentially associated with COVID-19 were collected. The reviewed literature were limited to adults ≥18 years.Results: Although most of the existing evidence was based on case reports or case series without a long-term follow-up, a variety of autoimmune/rheumatic manifestations were associated with COVID-19. The manifestations that have a consistent association with COVID-19 include autoimmune cytopenia, cutaneous vasculitis, encephalitis, and Guillain-Barre syndrome. Such association is conflicting as regards to antiphospholipid syndrome, hemophagocytic lymphohistiocytosis, and myasthenia gravis.Conclusion: Our systematic review indicated the potential of the COVID-19 virus to trigger a myriad of autoimmune and rheumatic manifestations, which should be considered amid global efforts to combat COVID-19.

show abstract

“…As a result, many national and international societies proposed specific recommendations to help both physicians and patients to face the pandemic (10-13). Although cases of psoriasis exacerbation in COVID-19 infected patients have been reported (14,15), little is known about how the pandemic-related lockdown has influenced the life of COVID-19 negative psoriatic patients. The aim of this study was to describe the impact of the lockdown during the COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biological therapies, analyzing the clinical course of the disease, therapy management and patients' psychological status.…”

Section: Introductionmentioning

confidence: 99%

The impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biological therapies

Pirrò

Caldarola

Chiricozzi

et al. 2020

Journal of Dermatological Treatment

View full text Add to dashboard Cite

Background: The beginning of 2020 has been marked by COVID-19 pandemic, with a strong impact on several national health systems worldwide. Objective: To describe the impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biologics. Methods: A telephone survey was conducted in May 4-10 2020 about the Italian lockdown period (March 9-May 3 2020) in a cohort of psoriatic patients treated with biologics, asking about any exposure to COVID-19, disease status, continuation of therapy, work activity and psychological status through Hospital Anxiety and Depression Scale (HADS), Perceived Stress Scale (PSS) and Brief Resilience Scale (BRS). Results: 226 patients were interviewed, with no COVID-19 positive cases. Sixty-three of 226 (27.9%) described worsening of the disease with a correlation to drug withdrawal [43/226 (19%)]. Correlation was also found between the worsening of psoriasis and HADS anxiety, HADS depression, BRS and PSS abnormal scores considered both as categorical and continuous variables. No correlation was found between worsening of psoriasis and work activity. Conclusion: Uncertainty about whether biologics could increase the risk of SARS-CoV-2 infection led to drug withdrawal with subsequent worsening of psoriasis. Moreover, psychological status also had a direct influence on the clinical course of the disease.

show abstract

Covid‐19 and exacerbation of psoriasis

Cited by 63 publications

References 5 publications

Pustular psoriasis exacerbated by COVID ‐19 in a patient with the history of psoriasis

Pustular psoriasis exacerbated by COVID ‐19 in a patient with the history of psoriasis

Autoimmune and Rheumatic Manifestations Associated With COVID-19 in Adults: An Updated Systematic Review

The impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biological therapies

Contact Info

Product

Resources

About